NCT01254422View on ClinicalTrials.gov

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 2, 2010

Primary Completion Date

September 28, 2012

Study Completion Date

January 31, 2013

Conditions
Dengue FeverDengue Hemorrhagic Fever
Interventions
BIOLOGICAL

Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension

BIOLOGICAL

Placebo: NaCl 0.9%

0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension

Trial Locations (4)

30990

Ipoh, Perak

59100

Kuala Lumpur

70300

Negeri Sembilan

93586

Kuching, Sarawak

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY